Biocardia Inc (BCDA)

$1.42 +0.03 (2.16%)
Market Cap 15.07M
Revenue (ttm) 60,000.00
Net Income (ttm) -7.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13,250.00%
Debt to Equity Ratio 0.00
Volume 54,700
Avg Vol 84,928
Day's Range N/A - N/A
Shares Out 10.61M
Stochastic %K 86%
Beta 0.56
Analysts Sell
Price Target $15.50

Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 226 0120
Fax: 650 631 3731
Address:
320 Soquel Way, Sunnyvale, United States
TheUnmaker
TheUnmaker Jan. 10 at 12:39 PM
$TNXP $HSCS $BCDA just starting to heat up.
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Jan. 10 at 12:59 AM
$BCDA We have to guess what the guessed News was they guessed would be in December and now must guess when the guessed News will be Released I guess.
1 · Reply
canievas
canievas Jan. 9 at 8:50 PM
$BCDA keep loading here I’m a long term investor here 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
mankind1
mankind1 Jan. 8 at 4:53 PM
$BCDA quiet...too quiet
2 · Reply
BillionerOfKing
BillionerOfKing Jan. 7 at 1:50 PM
$BCDA Current Stock Price: $1.27
0 · Reply
NineLinesCat
NineLinesCat Jan. 5 at 12:59 AM
$BCDA ...Happy New Year to all bcda traders. First full week of trading. Let's get news and lets get busy...
1 · Reply
chris_stocks
chris_stocks Dec. 31 at 10:09 PM
$BCDA they were supposed to meet with the FDA in December to seek a pathway toward approval. December is over. Has anyone heard anything about it? When will they hear from Japan?
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 30 at 2:33 PM
$BCDA PT Analyst Forecasts range from $6.00-$25.00. Average BCDA Price Target is $15.50. Impending News.
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 29 at 11:31 PM
$BCDA My idea : 1. BCDA will decide to find more Strategic Allies by reaching out, phone call after phone call. 2. BCDA must demonstrate payer interest, manufacturing readiness, and early access programs.
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 29 at 10:08 PM
$BCDA
0 · Reply
Latest News on BCDA
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

Dec 16, 2025, 8:00 AM EST - 4 weeks ago

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

Dec 1, 2025, 8:30 AM EST - 6 weeks ago

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

Nov 24, 2025, 8:15 AM EST - 7 weeks ago

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 12:11 AM EST - 2 months ago

BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

Nov 12, 2025, 4:40 PM EST - 2 months ago

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

Nov 5, 2025, 7:29 PM EST - 2 months ago

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

BioCardia Regains Compliance with Nasdaq Listing Requirements

Oct 2, 2025, 8:00 AM EDT - 3 months ago

BioCardia Regains Compliance with Nasdaq Listing Requirements

BioCardia Announces Pricing of Up To $12 Million Public Offering

Sep 18, 2025, 9:15 AM EDT - 4 months ago

BioCardia Announces Pricing of Up To $12 Million Public Offering

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

Sep 18, 2025, 7:00 AM EDT - 4 months ago

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

Sep 4, 2025, 9:00 AM EDT - 4 months ago

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 8:37 PM EDT - 5 months ago

BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 11, 2025, 9:15 AM EDT - 5 months ago

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

Aug 6, 2025, 3:18 PM EDT - 5 months ago

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

Aug 4, 2025, 6:00 AM EDT - 5 months ago

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

May 21, 2025, 8:30 AM EDT - 8 months ago

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:40 PM EDT - 8 months ago

BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

May 14, 2025, 4:05 PM EDT - 8 months ago

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

May 9, 2025, 4:28 PM EDT - 8 months ago

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Apr 11, 2025, 9:15 AM EDT - 9 months ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 11:30 PM EDT - 10 months ago

BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

Mar 31, 2025, 1:39 PM EDT - 10 months ago

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

BioCardia Reports 2024 Business Highlights and Financial Results

Mar 26, 2025, 4:30 PM EDT - 10 months ago

BioCardia Reports 2024 Business Highlights and Financial Results

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Mar 21, 2025, 8:30 AM EDT - 10 months ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

Mar 10, 2025, 9:15 AM EDT - 11 months ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Feb 27, 2025, 9:15 AM EST - 11 months ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Feb 13, 2025, 8:30 AM EST - 11 months ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

Jan 27, 2025, 9:15 AM EST - 1 year ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Dec 4, 2024, 8:30 AM EST - 1 year ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:49 PM EST - 1 year ago

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Sep 18, 2024, 8:30 AM EDT - 1 year ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Sep 9, 2024, 4:05 PM EDT - 1 year ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

Aug 29, 2024, 8:30 AM EDT - 1 year ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 21, 2024, 7:00 AM EDT - 1 year ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:53 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Jul 17, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

Jun 7, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

BioCardia Announces Reverse Stock Split

May 21, 2024, 5:00 PM EDT - 1 year ago

BioCardia Announces Reverse Stock Split

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

May 14, 2024, 11:00 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 14, 2024, 4:02 PM EDT - 1 year ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 9, 2024, 7:00 AM EDT - 1 year ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

May 1, 2024, 7:00 AM EDT - 1 year ago

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Apr 25, 2024, 9:00 AM EDT - 1 year ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 8:00 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Mar 27, 2024, 4:00 PM EDT - 1 year ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Mar 13, 2024, 7:00 AM EDT - 2 years ago

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Mar 12, 2024, 7:00 AM EDT - 2 years ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Mar 4, 2024, 8:00 AM EST - 2 years ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

Feb 8, 2024, 7:00 AM EST - 2 years ago

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

TheUnmaker
TheUnmaker Jan. 10 at 12:39 PM
$TNXP $HSCS $BCDA just starting to heat up.
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Jan. 10 at 12:59 AM
$BCDA We have to guess what the guessed News was they guessed would be in December and now must guess when the guessed News will be Released I guess.
1 · Reply
canievas
canievas Jan. 9 at 8:50 PM
$BCDA keep loading here I’m a long term investor here 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
mankind1
mankind1 Jan. 8 at 4:53 PM
$BCDA quiet...too quiet
2 · Reply
BillionerOfKing
BillionerOfKing Jan. 7 at 1:50 PM
$BCDA Current Stock Price: $1.27
0 · Reply
NineLinesCat
NineLinesCat Jan. 5 at 12:59 AM
$BCDA ...Happy New Year to all bcda traders. First full week of trading. Let's get news and lets get busy...
1 · Reply
chris_stocks
chris_stocks Dec. 31 at 10:09 PM
$BCDA they were supposed to meet with the FDA in December to seek a pathway toward approval. December is over. Has anyone heard anything about it? When will they hear from Japan?
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 30 at 2:33 PM
$BCDA PT Analyst Forecasts range from $6.00-$25.00. Average BCDA Price Target is $15.50. Impending News.
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 29 at 11:31 PM
$BCDA My idea : 1. BCDA will decide to find more Strategic Allies by reaching out, phone call after phone call. 2. BCDA must demonstrate payer interest, manufacturing readiness, and early access programs.
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 29 at 10:08 PM
$BCDA
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Dec. 29 at 7:24 PM
$BCDA Funny how the math worked out for me at $1.23. I am back in, finally. Still no BCDAW, I see. Oh well. C'mon, CardiAMP!
1 · Reply
Raycloser
Raycloser Dec. 29 at 2:42 PM
$BCDA looks like a 400,000 block of shares traded right at the open
0 · Reply
FedericoC
FedericoC Dec. 29 at 11:34 AM
$BCDA Unusual PM Volume 🤔
0 · Reply
chris_stocks
chris_stocks Dec. 29 at 10:43 AM
$BCDA nice movement earlier to 1.50
0 · Reply
TheUnmaker
TheUnmaker Dec. 28 at 12:26 PM
$BCDA dilution killed this ticker.. this will drop out harder after any small pump.
2 · Reply
NineLinesCat
NineLinesCat Dec. 26 at 4:41 PM
$BCDA ...tax harvest coming next week. Possible dip. Looking towards a January rise and a bright new year. Good things coming...
1 · Reply
BourbonBulls
BourbonBulls Dec. 25 at 9:39 AM
$BCDA Market tolerance narrows as uncertainty lingers, as investors weigh durability over pace. A coherent operating roadmap would be catalytic.
0 · Reply
builderup
builderup Dec. 23 at 4:25 PM
Like the set up. Think I’m gonna get in and ride these into 2026. Happy Holidays everyone. Let’s make 2026 the best ones yet. $ICU $BCDA
1 · Reply
doyoujetset
doyoujetset Dec. 22 at 5:10 PM
$BCDA Consolidation ready to move up to test $1.50⏳ Setup for more fundamental updates with Japan/FDA/Commercialization.
0 · Reply
Raycloser
Raycloser Dec. 20 at 4:05 AM
$BCDA why are the insider purchases so modest?
1 · Reply
canievas
canievas Dec. 18 at 2:17 PM
$BCDA WE NED TO BUY AS MUCH YOU CAN HERE 🚀🚀🚀🚀🚀🚀
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 18 at 1:35 AM
$BCDA CEO purchased 1,100 shares at $1.31 for a total of $1,444. Altman Peter now owns 267,966 shares. https://ceo-buys.com
2 · Reply